The subject of the invention relates to various new salts of palbociclib, furthermore to their hydrate and solvate forms, such as the palbociclib hydrogen bromide (1:1) salt, the palbociclib hydrogen bromide (1:2) dihydrate salt, the palbociclib hydrogen chloride (1:1) salt Form E, the palbociclib sulphate (2:1) dihydrate salt, the palbociclib camsylate (1:1) salt, the palbociclib napsylate (1:1) salt, the palbociclib napsylate (1:2) dihydrate salt, the palbociclib tosylate (1:1) salt, the palbociclib citrate (1:1) monohydrate salt, the palbociclib maleate (1:1) salt Form I, the palbociclib maleate (1:1) salt Form II and the palbociclib oxalate (1:1) salt. The subject of the invention also relates to the production of the above palbociclib salts, medicinal preparations containing these and the medical use of the above forms.
